Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823780 | 1.00 | PIK3CA (0.51) | PIK3CAMTORPIK3CGCD274MAP4K4 | |
| SCHEMBL826417 | 0.95 | PIK3CA (0.52) | PIK3CAMTORPIK3CGCD274MAP4K4 | |
| SCHEMBL823662 | 0.95 | PIK3CA (0.52) | PIK3CAMTORPIK3CGCD274MAP4K4 | |
| SCHEMBL825991 | 0.91 | PIK3CA (0.48) | PIK3CAMTORPIK3CGMAP4K4 | |
| SCHEMBL823658 | 0.91 | PIK3CA (0.48) | PIK3CAMTORPIK3CGMAP4K4 | |
| SCHEMBL3336059 | 0.87 | CD274 (0.54) | PIK3CAMTORPIK3CGCD274HPGDS | |
| SCHEMBL3336061 | 0.87 | CD274 (0.54) | PIK3CAMTORPIK3CGCD274HPGDS | |
| SCHEMBL823739 | 0.86 | BRAF (0.43) | PIK3CAMTORPIK3CGMAP4K4 | |
| SCHEMBL826441 | 0.86 | BRAF (0.43) | PIK3CAMTORPIK3CGMAP4K4 | |
| SCHEMBL823752 | 0.85 | JAK1 (0.44) | PIK3CAMTORPIK3CGMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | claimed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | PIK3CA 1189/4885MTOR 4090/4885PIK3CG 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.